Skip to content

To study the role of suprachoroidal triamcinolone acetate (corticosteroid) injection in patients with diabetic retinopathy and diabetic macular edema

To study the role of suprachoroidal triamcinolone acetate injection in patients with diabetic retinopathy and diabetic macular edema - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/05/087763
Enrollment
51
Registered
2025-05-28
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H350- Background retinopathy and retinalvascular changes Health Condition 2: H36- Retinal disorders in diseases classified elsewhere

Interventions

Intervention1: suprachoroidal Triamcinolone Acetate injection: Under aseptic conditions (using 0.5% betadine 10% solution) The subject eye will be anesthetised by eyedrop Proparacaine. Next with the

Sponsors

GSVM Medical College Kanpur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients willing to participate or ready for followup for at least 6 months. All patients of diabetic retinopathy and macular edema on FFA & OCT.

Exclusion criteria

Exclusion criteria: Patients not willing to participate or ready for followup. Patients with HTN (160/110mmHg) Patients with any ocular infection, raised Intraocular pressure (IOP), any corneal pathology, thinned sclera, scleritis, staphyloma, or any other anterior segment pathology except Pseudophakic patients. Patients diagnosed of any other retinal or vitreous pathologies except diabetic retinopathy and diabetic macular edema. Diabetic retinopathy old case of Diabetic Macular Edema. Patients having severe, very severe diabetic retinopathy, proliferative diabetic retinopathy and diabetic macular edema

Design outcomes

Primary

MeasureTime frame
Improvement in best corrected visual acuity Timepoint: 0, 1 month, 2 month, 3 month 6 month

Secondary

MeasureTime frame
Reduction in macular edemaTimepoint: pre intervention 1 month, 6 month

Countries

India

Contacts

Public ContactDr Deepak Kumar

GSVM Medical College Kanpur

dkboss9793@gmail.com9793899874

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026